Regentis Biomaterials Secures New U.S. Patent for GelrinC
Ticker: RGNT · Form: 6-K · Filed: Dec 18, 2025 · CIK: 1912966
| Field | Detail |
|---|---|
| Company | Regentis Biomaterials Ltd. (RGNT) |
| Form Type | 6-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, intellectual-property, medical-device
TL;DR
Regentis Biomaterials just got a new US patent for their GelrinC cartilage repair product. Big win for IP.
AI Summary
Regentis Biomaterial Ltd. announced on December 18, 2025, that it has been granted a new U.S. patent for its GelrinC product, an off-the-shelf regenerative cartilage repair solution. This patent is expected to strengthen the company's intellectual property portfolio for its innovative medical device.
Why It Matters
The new patent for GelrinC could enhance Regentis Biomaterials' market position and protect its innovative cartilage repair technology from competitors.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a patent grant, which is generally positive news with low immediate risk.
Key Players & Entities
- Regentis Biomaterials Ltd. (company) — Filer of the report and recipient of the patent
- GelrinC (product) — The regenerative cartilage repair product for which the patent was granted
- December 18, 2025 (date) — Date of the press release and the patent announcement
- 001-42834 (company_id) — Commission file number for Regentis Biomaterials Ltd.
FAQ
What is the specific title of the press release attached to this 6-K filing?
The press release is titled 'Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.'
What is the primary product mentioned in the filing for which a patent was granted?
The primary product mentioned is GelrinC, an off-the-shelf regenerative cartilage repair product.
On what date was the press release issued and incorporated into this filing?
The press release was issued on December 18, 2025.
What is the Commission file number for Regentis Biomaterials Ltd.?
The Commission file number for Regentis Biomaterials Ltd. is 001-42834.
Does Regentis Biomaterials Ltd. file annual reports under Form 20-F or Form 40-F?
Regentis Biomaterials Ltd. files annual reports under Form 20-F.
Filing Stats: 208 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2025-12-18 08:48:52
Filing Documents
- ea0270155-6k_regentis.htm (6-K) — 11KB
- ea027015501ex99-1_regentis.htm (EX-99.1) — 12KB
- 0001213900-25-123065.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Regentis Biomaterials Ltd. Date: December 18, 2025 By: /s/ Ehud Geller Name: Ehud Geller Title: Chairman 3